No connection

Search Results

AVNS vs RIGL

AVNS
Avanos Medical, Inc.
BEARISH
Price
$13.09
Market Cap
$607.6M
Sector
Healthcare
AI Confidence
68%
RIGL
Rigel Pharmaceuticals, Inc.
BULLISH
Price
$32.43
Market Cap
$599.3M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
AVNS
--
RIGL
1.66
Forward P/E
AVNS
13.78
RIGL
6.76
P/B Ratio
AVNS
0.78
RIGL
1.52
P/S Ratio
AVNS
0.87
RIGL
2.04
EV/EBITDA
AVNS
9.0
RIGL
3.89

Profitability

Gross Margin
AVNS
52.28%
RIGL
82.02%
Operating Margin
AVNS
0.28%
RIGL
33.19%
Profit Margin
AVNS
-67.0%
RIGL
124.72%
ROE
AVNS
-46.68%
RIGL
185.94%
ROA
AVNS
1.58%
RIGL
23.15%

Growth

Revenue Growth
AVNS
4.3%
RIGL
21.2%
Earnings Growth
AVNS
--
RIGL
1598.7%

Financial Health

Debt/Equity
AVNS
0.17
RIGL
0.14
Current Ratio
AVNS
2.38
RIGL
2.42
Quick Ratio
AVNS
1.23
RIGL
2.08

Dividends

Dividend Yield
AVNS
--
RIGL
--
Payout Ratio
AVNS
0.0%
RIGL
0.0%

AI Verdict

AVNS BEARISH

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 2/9, indicating significant operational and profitability concerns. Despite a low Price/Book and Price/Sales ratio suggesting potential value, the company is unprofitable with a -67% profit margin and negative ROE of -46.68%, undermining valuation appeal. While revenue growth is positive at 4.3% YoY and recent earnings surprises have been strong, the lack of sustained profitability, deteriorating insider sentiment, and poor long-term price performance (-72.6% over 5 years) raise serious concerns. The absence of Altman Z-Score and key financial data limits confidence, but current signals point to a distressed or speculative investment.

Strengths
Revenue growth of 4.3% YoY shows top-line resilience in a challenging sector environment
Gross margin of 52.28% indicates strong pricing power and cost control at the production level
Low valuation multiples: P/B of 0.78 and P/S of 0.87 suggest potential undervaluation relative to book and sales
Risks
Piotroski F-Score of 2/9 signals severe financial weakness, particularly in profitability and leverage metrics
Profit margin of -67% and ROE of -46.68% indicate deep unprofitability and inefficient use of equity
Missing Altman Z-Score prevents definitive distress assessment, but negative earnings and ROE imply high bankruptcy risk
RIGL BULLISH

RIGL exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a very conservative debt profile (Debt/Equity 0.14). The company is severely undervalued, trading at $32.43, which is significantly below both its Graham Number ($96.8) and its growth-based intrinsic value ($574.66). While technical trends and insider sentiment are currently bearish, the explosive earnings growth (1598.7% YoY) and a P/E ratio of 1.66 suggest a massive valuation gap. The transition from historical losses to consistent earnings beats indicates a successful pivot to profitability.

Strengths
Extreme undervaluation with a P/E of 1.66 and Price/Book of 1.52
Strong financial health indicated by a Piotroski F-Score of 7/9
Explosive earnings growth (1598.7% YoY) and consistent earnings beats
Risks
Bearish technical trend (0/100) suggesting short-term price pressure
Negative insider sentiment with recent selling activity
Potential for non-recurring gains inflating the reported profit margin (124.72%)

Compare Another Pair

AVNS vs RIGL: Head-to-Head Comparison

This page compares Avanos Medical, Inc. (AVNS) and Rigel Pharmaceuticals, Inc. (RIGL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile